Oruka Therapeutics reported mid-stage results for ORKA-001, a long-acting IL-23 monoclonal antibody, in plaque psoriasis and also provided updated exposure analysis supporting once-per-year dosing. Oruka said 63% of treated patients achieved complete skin clearance in the mid-stage trial. Oruka also indicated that pharmacokinetic updates supported the potential for annual injection scheduling. The company still needs late-stage trials to confirm benefit and safety, but the readout increases the competitive pressure on established IL-23 blockbusters that require multiple injections. The data were framed by analysts as an “outright win” over Skyrizi in the context of trial outcomes, intensifying attention on differentiated dosing convenience plus efficacy.